JOP20220093A1 - تركيبة صيدلانية تشتمل على سيليكسيباغ - Google Patents

تركيبة صيدلانية تشتمل على سيليكسيباغ

Info

Publication number
JOP20220093A1
JOP20220093A1 JOP/2022/0093A JOP20220093A JOP20220093A1 JO P20220093 A1 JOP20220093 A1 JO P20220093A1 JO P20220093 A JOP20220093 A JO P20220093A JO P20220093 A1 JOP20220093 A1 JO P20220093A1
Authority
JO
Jordan
Prior art keywords
selexipag
pharmaceutical composition
diphenylpyrazin
butyloxy
isopropylamino
Prior art date
Application number
JOP/2022/0093A
Other languages
English (en)
Inventor
Alexandra Schlicker-Spain
Marc Patrik Schrader
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JOP20220093A1 publication Critical patent/JOP20220093A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية تتألف من 2-{4-[N-(5,6-ثنائي فينيل بيرازين-2-يل)-N-أيزوبروبيل أمينو]بوتيل أوكسي}-N-(ميثيل سلفونيل)أسيتاميد (سيليكيباغ، NS-304, ACT-293987) والتي تكون مناسبة للإعطاء فمويًا (اختصارًا p.o.).
JOP/2022/0093A 2019-10-23 2020-10-22 تركيبة صيدلانية تشتمل على سيليكسيباغ JOP20220093A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019078905 2019-10-23
PCT/EP2020/079698 WO2021078835A1 (en) 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
JOP20220093A1 true JOP20220093A1 (ar) 2023-01-30

Family

ID=75620412

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0093A JOP20220093A1 (ar) 2019-10-23 2020-10-22 تركيبة صيدلانية تشتمل على سيليكسيباغ

Country Status (14)

Country Link
US (1) US20220401441A1 (ar)
EP (1) EP4048235A1 (ar)
JP (1) JP2022553313A (ar)
KR (1) KR20220087443A (ar)
CN (1) CN114555088A (ar)
AU (1) AU2020369912A1 (ar)
BR (1) BR112022007207A2 (ar)
CA (1) CA3154802A1 (ar)
EC (1) ECSP22040921A (ar)
IL (1) IL292354A (ar)
JO (1) JOP20220093A1 (ar)
MX (1) MX2022004882A (ar)
PE (1) PE20221455A1 (ar)
WO (1) WO2021078835A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023195953A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising selexi̇pag
WO2023195954A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising a solid dispersion of selexi̇pag
WO2023195957A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising selexi̇pag processed with wet granulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (ar) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2009107736A1 (ja) 2008-02-28 2009-09-03 日本新薬株式会社 線維化抑制剤
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8394793B2 (en) 2008-06-23 2013-03-12 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
JP5527205B2 (ja) 2008-06-23 2014-06-18 日本新薬株式会社 脊柱管狭窄症治療剤
BRPI1015936B1 (pt) 2009-06-26 2021-07-13 Nippon Shinyaku Co., Ltd. Cristal de forma i de 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopro pilamino]butilóxi}-n (metilsulfonil)acetamida e composição farmacêutica
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
CN103874480A (zh) 2011-08-12 2014-06-18 阿森迪斯药物股份有限公司 前列环素的缓释组合物
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
MX2018006343A (es) * 2015-12-02 2018-08-01 Nippon Shinyaku Co Ltd Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin- 2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida.
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
KR20200123447A (ko) * 2018-02-21 2020-10-29 니뽄 신야쿠 가부시키가이샤 입상 조성물, 입상 조성물의 제조 방법, 및 입상 조성물의 용출성 개선 방법
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法

Also Published As

Publication number Publication date
AU2020369912A1 (en) 2022-04-14
CA3154802A1 (en) 2021-04-29
MX2022004882A (es) 2022-08-04
PE20221455A1 (es) 2022-09-21
US20220401441A1 (en) 2022-12-22
ECSP22040921A (es) 2022-06-30
KR20220087443A (ko) 2022-06-24
CN114555088A (zh) 2022-05-27
EP4048235A1 (en) 2022-08-31
IL292354A (en) 2022-06-01
JP2022553313A (ja) 2022-12-22
WO2021078835A1 (en) 2021-04-29
BR112022007207A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
JOP20220093A1 (ar) تركيبة صيدلانية تشتمل على سيليكسيباغ
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
NO20082547L (no) Orale formuleringer omfattende tigecycline
MX2021004000A (es) Derivados de piperidina.
EP3384911A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING 2- {4- [N- (5,6-DIPHENYLPYRAZIN-2-YL) -N-ISOPROPYLAMINO] BUTYLOXY} -N- (METHYLSULFONYL) ACETAMIDE
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2021014680A (es) Derivado de benzotriazol.
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MX2010001243A (es) Composicion anti-inflamatoria.
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
MX2022007988A (es) Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
CR20220174A (es) Composición farmacéutica que comprende selexipag
PH12017501736A1 (en) Indole derivatives
WO2020055359A3 (en) Oral dosage form of sorafenib tosylate
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
WO2019151965A3 (en) Solid oral pharmaceutical compositions comprising apixaban
MX2022005503A (es) Composiciones farmaceuticas de apixaban de desintegracion oral.